Royal Bank of Canada
ACRS icon

Royal Bank of Canada’s Aclaris Therapeutics ACRS Stock Holding History

Royal Bank of Canada’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23K Buy
4,394
+4,306
+4,893% +$19.2K ﹤0.01% 6244
2026
Q1 		$0 Sell
88
-2,530
-97% -$8.54K ﹤0.01% 7043
2025
Q4 		$8K Sell
2,618
-25,662
-91% -$64.8K ﹤0.01% 6505
2025
Q3 		$54K Buy
28,280
+19,859
+236% +$34.6K ﹤0.01% 5784
2025
Q2 		$13K Buy
8,421
+8,375
+18,207% +$11.3K ﹤0.01% 6396
2025
Q1 		$0 Sell
46
-727
-94% -$1.55K ﹤0.01% 6761
2024
Q4 		$2K Buy
773
+715
+1,233% +$1.78K ﹤0.01% 6683
2024
Q3 		$0 Sell
58
-4,189
-99% -$5.14K ﹤0.01% 6784
2024
Q2 		$5K Buy
4,247
+1,282
+43% +$1.51K ﹤0.01% 6519
2024
Q1 		$4K Sell
2,965
-20,423
-87% -$24.4K ﹤0.01% 6475
2023
Q4 		$25K Buy
23,388
+10,083
+76% +$30.8K ﹤0.01% 6235
2023
Q3 		$92K Buy
13,305
+7,335
+123% +$62.7K ﹤0.01% 5430
2023
Q2 		$62K Buy
5,970
+1,435
+32% +$13K ﹤0.01% 5659
2023
Q1 		$36K Sell
4,535
-2,969
-40% -$37.7K ﹤0.01% 5785
2022
Q4 		$117K Buy
7,504
+6,673
+803% +$107K ﹤0.01% 5327
2022
Q3 		$13K Buy
831
+484
+139% +$7.63K ﹤0.01% 6293
2022
Q2 		$5K Sell
347
-2,790
-89% -$39.1K ﹤0.01% 6625
2022
Q1 		$54K Sell
3,137
-7,590
-71% -$104K ﹤0.01% 6029
2021
Q4 		$156K Buy
10,727
+5,581
+108% +$84.6K ﹤0.01% 5580
2021
Q3 		$93K Buy
5,146
+2,172
+73% +$34.8K ﹤0.01% 5750
2021
Q2 		$52K Sell
2,974
-541
-15% -$12.3K ﹤0.01% 6012
2021
Q1 		$89K Buy
3,515
+1,621
+86% +$31.7K ﹤0.01% 5536
2020
Q4 		$12K Buy
1,894
+1,520
+406% +$6.41K ﹤0.01% 6288
2020
Q3 		$1K Sell
374
-4,035
-92% -$9.03K ﹤0.01% 6379
2020
Q2 		$7K Sell
4,409
-3,555
-45% -$4.76K ﹤0.01% 5937
2020
Q1 		$8K Buy
7,964
+3,966
+99% +$5.4K ﹤0.01% 5881
2019
Q4 		$7K Buy
3,998
+3,353
+520% +$5.56K ﹤0.01% 6241
2019
Q3 		$1K Sell
645
-3,000
-82% -$4.26K ﹤0.01% 6379
2019
Q2 		$8K Sell
3,645
-1,261
-26% -$6.87K ﹤0.01% 6087
2019
Q1 		$29K Sell
4,906
-89
-2% -$590 ﹤0.01% 5455
2018
Q4 		$37K Sell
4,995
-2,059
-29% -$21.2K ﹤0.01% 5255
2018
Q3 		$102K Buy
7,054
+452
+7% +$7.75K ﹤0.01% 4851
2018
Q2 		$132K Buy
6,602
+85
+1% +$1.57K ﹤0.01% 4646
2018
Q1 		$114K Buy
6,517
+5,531
+561% +$117K ﹤0.01% 4628
2017
Q4 		$24K Sell
986
-1,219
-55% -$29.7K ﹤0.01% 5523
2017
Q3 		$57K Buy
2,205
+2,191
+15,650% +$58.7K ﹤0.01% 5332
2017
Q2 		$0 Sell
14
-312
-96% -$8.48K ﹤0.01% 6531
2017
Q1 		$10K Sell
326
-142
-30% -$4.09K ﹤0.01% 5954
2016
Q4 		$13K Buy
+468
New +$11.9K ﹤0.01% 5966

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Royal Bank of Canada's ACRS Position: Q2 2026 in Review

Royal Bank of Canada increased its Aclaris Therapeutics (ACRS) stake by 4,893% in Q2 2026, buying an estimated $19.2K and bringing the position to 4,394 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #6244.

Royal Bank of Canada first reported a position in ACRS in Q4 2016 and has held it in 39 quarters since. The position peaked at $156K in Q4 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Royal Bank of Canada held 4,394 shares of Aclaris Therapeutics worth $23K as of Q2 2026.
  • Royal Bank of Canada bought 4,306 Aclaris Therapeutics shares in Q2 2026, an estimated $19.2K.
  • Aclaris Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6244 holding.
  • Royal Bank of Canada first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • Royal Bank of Canada's Aclaris Therapeutics position peaked at $156K in Q4 2021.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.